RFK Jr's new vaccine panel votes against preservative in flu shots in shock move
A critical federal vaccine panel has recommended against seasonal influenza vaccines containing a specific preservative – a change likely to send shock through the global medical and scientific community and possibly impact future vaccine availability.
The panel was unilaterally remade by health secretary Robert F Kennedy Jr, a vaccine skeptic who has urged against the use of thimerosal despite a lack of evidence of real-world harm.
Across three votes, members voted in favor of restricting thimerosal in seasonal influenza vaccines across all age groups – with five in favor of the restriction, one abstention and one vote against.
'The risk from influenza is so much greater than the nonexistent – as far as we know – risk from thimerosal,' said Dr Cody Meissner, a panel member and professor of pediatrics at Dartmouth's Geisel School of Medicine who was the lone 'no' vote.
'I would hate for a person not to receive the influenza vaccine because the only availability preparation contains thimerosal – I find that very hard to justify.'
The panel, formally called the Advisory Committee for Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC), is a critical link in the vaccine distribution pipeline – informing health insurers and clinicians alike about which vaccines to give patients.
Kennedy fired all 17 former members of the panel in June, citing conflicts of interest, and appointed eight new members, all of whom are ideological allies of the secretary.
None of the new members have published written conflict of interest disclosures or been added to a Trump administration-developed conflict of interest tracker for ACIP members, as of Thursday morning.
'There is a very big difference between what was shared at the meeting versus what is reality,' said Dr Sean O'Leary, chair of the American Academy of Pediatrics Committee on Infectious Diseases. 'The science on thimerosal is settled, and the rhetoric being used to suggest otherwise is misleading and harmful.'
Rather than vote on an agenda that had once included seasonal recommendations for Covid-19 and the vaccine against human papilloma virus (HPV), ACIP added the controversial focus of thimerosal in vaccines. The panel affirmed that the influenza vaccine is recommended for Americans older than six months.
Related: RFK Jr will be 'personally responsible' for children's deaths by halting vaccine alliance funding, experts say
Although multiple studies have found no real-world harm, the preservative has been a talking point of anti-vaccine advocates for decades. Multiple representatives of physicians associations urged the panel to reject the recommendation against thimerosal in the meeting.
Thimerosal is used in about 5% of multidose seasonal influenza vials, and is known to be more cost effective than single-dose formulations. It is unclear how the vote will impact flu vaccine availability before the upcoming flu season, particularly for clinics that rely on such formulations.
Thimerosal has been used as a preservative in vaccines since before the second world war. In the early 2000s, thimerosal was removed from all routine pediatric and most adult vaccines as a precautionary measure – a decision that was criticized by experts who argued it sent mixed messages about a preservative that had not been found to cause harm. The issue has since been considered settled by mainstream medicine.
Thimerosal is an ethylmercury-based preservative. Ethylmercury is different from the kind of mercury found in seafood, called methylmercury. Ethylmercury has a much shorter half-life in the blood and brain, about seven days and 30 days respectively, compared to methylmercury, which has an approximately 44-58 day half-life and accumulates in the brain. The amount of ethylmercury contained in a flu vaccine (25 micrograms) is about half of that contained in a 3-ounce serving of canned tuna fish (40 micrograms).
Repeated, large studies conducted across several countries have found no association between thimerosal and neurological effects. A presentation from CDC career scientists that was initially expected to go through some of this substantial data was removed before the panel reconvened on Thursday.
In response to a question about the slapped down presentation, ACIP member Dr Robert Malone, a well-known anti-vaccine activist, said: 'That article was not authorized by the office of the secretary and was removed.'
The panel instead heard a presentation from Lyn Redwood, a nurse practitioner who founded the World Mercury Project, the predecessor to Kennedy's anti-vaccine advocacy group Children's Health Defense. Prior to the meeting, her presentation was found to include a reference to a study that appeared to be made up.
'This is an old issue that has been addressed in the past and there are many issues we could discuss,' said Meissner.
The best public interest journalism relies on first-hand accounts from people in the know.
If you have something to share on this subject you can contact us confidentially using the following methods.
Secure Messaging in the Guardian app
The Guardian app has a tool to send tips about stories. Messages are end to end encrypted and concealed within the routine activity that every Guardian mobile app performs. This prevents an observer from knowing that you are communicating with us at all, let alone what is being said.
If you don't already have the Guardian app, download it (iOS/Android) and go to the menu. Select 'Secure Messaging'.
SecureDrop, instant messengers, email, telephone and post
See our guide at theguardian.com/tips for alternative methods and the pros and cons of each.
Responding to criticism of Redwood's presentation, ACIP chair Dr Martin Kulldorff, a former Harvard professor who was fired for refusing the Covid-19 vaccine, said: 'It's inappropriate to dismiss a presentation just because the person does not have a PhD or MD.'
The decision from ACIP could have global implications, because vaccines used around the world rely on thimerosal as a preservative in multidose vials, which are less expensive.
'I know ACIP is focused on the US, but recommendations that the ACIP makes are followed among many countries around the world,' said Meissner.
'Removing thimerosal from all vaccines used in other countries, for example, is going to reduce access to these vaccines, it will increase costs, and I think it's important to note that no study has ever indicated any harm from thimerosal.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
30 minutes ago
- Medscape
Tool Predicts if Seniors with Cancer Can Stay Home Post Op
TOPLINE: A novel predictive model named STAYHOME effectively estimated the risk of losing the ability to live at home among older adults after cancer surgery, demonstrating good calibration with minimal deviation from observed risks. The model predicted a 2.4% and 3.4% risk for admission to a nursing home at 6 months and 12 months, respectively. METHODOLOGY: Older adults prioritize long-term functional independence, and the ability to return and stay at home after cancer surgery remains a key concern. However, current prognostic tools focus on short-term outcomes, lacking individualized long-term risk estimates. To estimate the risk of losing the ability to live at home post-surgery, researchers developed and internally validated a risk prediction model, named STAYHOME, among 97,353 community-dwelling older adults (median age, 76 years) who underwent cancer surgery between 2007 and 2019. The predictive model included preoperative variables such as age, sex, rural residence, previous cancer diagnosis, surgery type, frailty, receipt of home care support, receipt of neoadjuvant therapy, cancer site, and cancer stage. The primary outcome was the inability to stay at home after cancer surgery, defined as the time to admission to a nursing home, and was measured at 6 months and 12 months. TAKEAWAY: Overall, 2658 patients (2.7%) at 6 months and 3746 (3.8%) at 12 months were admitted to a nursing home post-surgery. The mean predicted risk of not staying home was 2.4% at 6 months and 3.4% at 12 months. The STAYHOME tool demonstrated a strong predictive capability, with areas under the curve of 0.76 and 0.75 for 6- and 12-month predictions, respectively. The tool also demonstrated minimal deviation from the observed risk for 6-month (0.33 percentage point on average; calibration slope, 1.27) and 12-month (0.46 percentage point on average; calibration slope, 1.17) predictions. The model's calibration was excellent for most predictors at 6 months and 12 months, with a deviation of < 0.8 percentage points from the observed probability; only age older than 85 years (1.13%), preoperative frailty (1.16%), and receipt of preoperative home care support (1.25%) exceeded the deviation of 1 percentage point at 12 months. Across risk deciles, deviations between predicted and observed probabilities were 0.1%-1.5% at 6 months and 0.1%-1.9% at 12 months, reflecting good calibration. The deviation for the slight overestimation at or above the seventh decile remained under 2% for both timepoints. IN PRACTICE: 'The STAYHOME tool demonstrated good discrimination and was well calibrated. Thus, it may be a useful tool to identify a specific group of individuals at risk of not remaining home,' the authors wrote. '[The tool] used information readily available to patients, care partners, and healthcare professionals and may be implemented to provide them with individualized risk estimates and improve surgical oncology care delivery and experience for older adults,' they concluded. SOURCE: This study, led by Julie Hallet, MD, Odette Cancer Centre, Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, was published online in JAMA Surgery. LIMITATIONS: The STAYHOME tool showed slightly reduced discrimination for predictor levels of preoperative frailty, preoperative home care use, receipt of neoadjuvant therapy, and having stage IV disease. The model was also less well calibrated at the extremes of the risk distribution, with a slight overestimation in higher-risk categories. DISCLOSURES: This study was funded by operating grants from the Canadian Institutes for Health Research, Ontario Cancer Research Institute, and ICES. One author reported receiving speaker fees from Ipsen, outside the submitted work. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Associated Press
35 minutes ago
- Associated Press
Enhancing Mobility and Independence: VARON Oxygen Concentrators Deliver a New Standard of Freedom and Care
NEW YORK, June 30, 2025 /PRNewswire/ -- For individuals managing respiratory conditions, every breath matters—and so does the freedom to move, explore, and live life on their own terms. At VARON, that belief is at the heart of everything we do. With our trusted line of portable oxygen concentrators, VARON continues to empower users across the globe with the freedom to breathe easier—wherever life takes them. Built on years of research, real-world feedback, and engineering excellence, VARON's portable oxygen concentrators—the VP-2 and VP-6 —remain leading choices for patients seeking mobility without compromise. These machines are not just reliable tools for supplemental oxygen—they're symbols of independence, quality, and care. 'Oxygen therapy should be a bridge to more freedom, not more restrictions,' said a VARON CEO. 'That's why our focus has always been on designing dependable, travel-ready solutions that reflect how people actually live their lives.' Trusted Performance for Life in Motion From day trips and errands to cross-country travel and everything in between, the VP series is built to move with users—not slow them down. These devices have earned a strong reputation among long-term users for their balance of performance, portability, and ease of use. The VP-6: Continuous Flow Power in a Portable Frame One of the most versatile options in its class, the VP-6 continuous portable oxygen concentrator delivers continuous flow oxygen in a compact, travel-friendly form—making it a perfect fit for patients who prefer the exprerience of continuous oxygen supply. It also features a replaceable rechargeable battery, timer settings, remote control, and even a nebulizer function, ensuring it's equipped for a wide range of daily and emergency scenarios. Trusted by users for its stability and versatility, the VP-6 continues to be a top choice for those who demand oxygen support without sacrificing freedom. The VP-2: Lightweight, Reliable, and Ready to Go The VP-2 pulse flow oxygen concentrator is ideal for users with active lifestyles who require oxygen support in a lighter, more compact format. This pulse dose concentrator weighs just a few pounds, yet delivers consistently responsive oxygen therapy that adjusts to the user's breathing rhythm. With long battery life, intuitive controls, and quiet performance, the VP-2 remains a go-to device for travel, social activities, and everyday movement. Why VARON Stands Out What sets VARON apart isn't just its devices—but the philosophy behind them. VARON engineers its products with the real-life needs of users in mind—putting equal weight on comfort, confidence, and care. Both the VP-2 and VP-6 portable oxygen concentrator reflect VARON's commitment to: Every detail, from power efficiency to button placement, is shaped by VARON's mission to make oxygen therapy more accessible and more empowering. Why VARON Stands Out Mobility doesn't stop at the device. VARON's comprehensive line of accessories and replacement parts like spare batteries, replacement filters, cannulas, and make the experience more seamless, and help users stay prepared and protected whether they are heading to the grocery store or crossing state lines. Proven by Experience, Driven by Purpose VP-2 and VP-6 portable oxygen concentrator users regularly share how VARON technology has transformed their daily lives—from regaining the confidence to travel, to joining family gatherings without anxiety, to simply stepping outside for a walk. These stories are what inspire our team every day. Backed by years of trusted performance and a drive to innovate, VARON continues to improve the experience of portable oxygen therapy. About VARON VARON is a leading name in respiratory care, known for its innovation in portable and home-use oxygen concentrators. With a deep focus on mobility, user comfort, and dependable performance, VARON helps users around the world live fully—without letting respiratory challenges define their boundaries. Live freely. Breathe fully. Go with VARON. MEDIA CONTACT: VARON Oxygen Solutions Email: [email protected] Website: View original content to download multimedia: SOURCE Varon oxygen concentrator
Yahoo
40 minutes ago
- Yahoo
Enhancing Mobility and Independence: VARON Oxygen Concentrators Deliver a New Standard of Freedom and Care
NEW YORK, June 30, 2025 /PRNewswire/ -- For individuals managing respiratory conditions, every breath matters—and so does the freedom to move, explore, and live life on their own terms. At VARON, that belief is at the heart of everything we do. With our trusted line of portable oxygen concentrators, VARON continues to empower users across the globe with the freedom to breathe easier—wherever life takes them. Built on years of research, real-world feedback, and engineering excellence, VARON's portable oxygen concentrators—the VP-2 and VP-6—remain leading choices for patients seeking mobility without compromise. These machines are not just reliable tools for supplemental oxygen—they're symbols of independence, quality, and care. "Oxygen therapy should be a bridge to more freedom, not more restrictions," said a VARON CEO. "That's why our focus has always been on designing dependable, travel-ready solutions that reflect how people actually live their lives." Trusted Performance for Life in Motion From day trips and errands to cross-country travel and everything in between, the VP series is built to move with users—not slow them down. These devices have earned a strong reputation among long-term users for their balance of performance, portability, and ease of use. The VP-6: Continuous Flow Power in a Portable Frame One of the most versatile options in its class, the VP-6 continuous portable oxygen concentrator delivers continuous flow oxygen in a compact, travel-friendly form—making it a perfect fit for patients who prefer the exprerience of continuous oxygen supply. It also features a replaceable rechargeable battery, timer settings, remote control, and even a nebulizer function, ensuring it's equipped for a wide range of daily and emergency scenarios. Trusted by users for its stability and versatility, the VP-6 continues to be a top choice for those who demand oxygen support without sacrificing freedom. The VP-2: Lightweight, Reliable, and Ready to Go The VP-2 pulse flow oxygen concentrator is ideal for users with active lifestyles who require oxygen support in a lighter, more compact format. This pulse dose concentrator weighs just a few pounds, yet delivers consistently responsive oxygen therapy that adjusts to the user's breathing rhythm. With long battery life, intuitive controls, and quiet performance, the VP-2 remains a go-to device for travel, social activities, and everyday movement. Why VARON Stands Out What sets VARON apart isn't just its devices—but the philosophy behind them. VARON engineers its products with the real-life needs of users in mind—putting equal weight on comfort, confidence, and care. Both the VP-2 and VP-6 portable oxygen concentrator reflect VARON's commitment to: Smart, responsive oxygen delivery Reliable battery solutions and power options Quiet, discreet operation for comfort in public spaces Lightweight builds and ergonomic designs Simple interfaces, suited for users of all ages Every detail, from power efficiency to button placement, is shaped by VARON's mission to make oxygen therapy more accessible and more empowering. Why VARON Stands Out Mobility doesn't stop at the device. VARON's comprehensive line of accessories and replacement parts like spare batteries, replacement filters, cannulas, and make the experience more seamless, and help users stay prepared and protected whether they are heading to the grocery store or crossing state lines. Proven by Experience, Driven by Purpose VP-2 and VP-6 portable oxygen concentrator users regularly share how VARON technology has transformed their daily lives—from regaining the confidence to travel, to joining family gatherings without anxiety, to simply stepping outside for a walk. These stories are what inspire our team every day. Backed by years of trusted performance and a drive to innovate, VARON continues to improve the experience of portable oxygen therapy. About VARON VARON is a leading name in respiratory care, known for its innovation in portable and home-use oxygen concentrators. With a deep focus on mobility, user comfort, and dependable performance, VARON helps users around the world live fully—without letting respiratory challenges define their boundaries. Live freely. Breathe fully. Go with VARON. MEDIA CONTACT: VARON Oxygen SolutionsEmail: official@ View original content to download multimedia: SOURCE Varon oxygen concentrator Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data